The global Biologic Medical Product market size was valued at US$ million in 2024 and is forecast to a readjusted size of USD million by 2031 with a CAGR of %during review period.
Biological products include a wide range of products such as vaccines, blood and blood components, allergenics, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins. Biologics can be composed of sugars, proteins, or nucleic acids or complex combinations of these substances, or may be living entities such as cells and tissues. Biologics are isolated from a variety of natural sources - human, animal, or microorganism - and may be produced by biotechnology methods and other cutting-edge technologies. Gene-based and cellular biologics, for example, often are at the forefront of biomedical research, and may be used to treat a variety of medical conditions for which no other treatments are available.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report is a detailed and comprehensive analysis for global Biologic Medical Product market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Biologic Medical Product market size and forecasts, in consumption value ($ Million), 2020-2031
Global Biologic Medical Product market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Biologic Medical Product market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Biologic Medical Product market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Biologic Medical Product
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Biologic Medical Product market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Amgen, AbbVie, Pfizer, Sanofi-Aventis, Johnson & Johnson, Novo Nordisk, Eli Lilly, Novartis, Merck, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Biologic Medical Product market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Monoclonal Antibodies
Colony-Stimulating Factor
Interferon
Erythropoietin
Insulin
Vaccines
Growth Hormones
Others
麻豆原创 segment by Application
Tumor
Diabetes
Cardiovascular
Hemophilia
Others
麻豆原创 segment by players, this report covers
Roche
Amgen
AbbVie
Pfizer
Sanofi-Aventis
Johnson & Johnson
Novo Nordisk
Eli Lilly
Novartis
Merck
Sun
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Ganlee
United Laboratories
Teva Pharmaceutical
MYLAN
Sun Pharma
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Biologic Medical Product product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Biologic Medical Product, with revenue, gross margin, and global market share of Biologic Medical Product from 2020 to 2025.
Chapter 3, the Biologic Medical Product competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Biologic Medical Product market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Biologic Medical Product.
Chapter 13, to describe Biologic Medical Product research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Biologic Medical Product by Type
1.3.1 Overview: Global Biologic Medical Product 麻豆原创 Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Biologic Medical Product Consumption Value 麻豆原创 Share by Type in 2024
1.3.3 Monoclonal Antibodies
1.3.4 Colony-Stimulating Factor
1.3.5 Interferon
1.3.6 Erythropoietin
1.3.7 Insulin
1.3.8 Vaccines
1.3.9 Growth Hormones
1.3.10 Others
1.4 Global Biologic Medical Product 麻豆原创 by Application
1.4.1 Overview: Global Biologic Medical Product 麻豆原创 Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Tumor
1.4.3 Diabetes
1.4.4 Cardiovascular
1.4.5 Hemophilia
1.4.6 Others
1.5 Global Biologic Medical Product 麻豆原创 Size & Forecast
1.6 Global Biologic Medical Product 麻豆原创 Size and Forecast by Region
1.6.1 Global Biologic Medical Product 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Biologic Medical Product 麻豆原创 Size by Region, (2020-2031)
1.6.3 North America Biologic Medical Product 麻豆原创 Size and Prospect (2020-2031)
1.6.4 Europe Biologic Medical Product 麻豆原创 Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Biologic Medical Product 麻豆原创 Size and Prospect (2020-2031)
1.6.6 South America Biologic Medical Product 麻豆原创 Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Biologic Medical Product 麻豆原创 Size and Prospect (2020-2031)
2 Company Profiles
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Biologic Medical Product Product and Solutions
2.1.4 Roche Biologic Medical Product Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 Roche Recent Developments and Future Plans
2.2 Amgen
2.2.1 Amgen Details
2.2.2 Amgen Major Business
2.2.3 Amgen Biologic Medical Product Product and Solutions
2.2.4 Amgen Biologic Medical Product Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Amgen Recent Developments and Future Plans
2.3 AbbVie
2.3.1 AbbVie Details
2.3.2 AbbVie Major Business
2.3.3 AbbVie Biologic Medical Product Product and Solutions
2.3.4 AbbVie Biologic Medical Product Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 AbbVie Recent Developments and Future Plans
2.4 Pfizer
2.4.1 Pfizer Details
2.4.2 Pfizer Major Business
2.4.3 Pfizer Biologic Medical Product Product and Solutions
2.4.4 Pfizer Biologic Medical Product Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Pfizer Recent Developments and Future Plans
2.5 Sanofi-Aventis
2.5.1 Sanofi-Aventis Details
2.5.2 Sanofi-Aventis Major Business
2.5.3 Sanofi-Aventis Biologic Medical Product Product and Solutions
2.5.4 Sanofi-Aventis Biologic Medical Product Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Sanofi-Aventis Recent Developments and Future Plans
2.6 Johnson & Johnson
2.6.1 Johnson & Johnson Details
2.6.2 Johnson & Johnson Major Business
2.6.3 Johnson & Johnson Biologic Medical Product Product and Solutions
2.6.4 Johnson & Johnson Biologic Medical Product Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Johnson & Johnson Recent Developments and Future Plans
2.7 Novo Nordisk
2.7.1 Novo Nordisk Details
2.7.2 Novo Nordisk Major Business
2.7.3 Novo Nordisk Biologic Medical Product Product and Solutions
2.7.4 Novo Nordisk Biologic Medical Product Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Novo Nordisk Recent Developments and Future Plans
2.8 Eli Lilly
2.8.1 Eli Lilly Details
2.8.2 Eli Lilly Major Business
2.8.3 Eli Lilly Biologic Medical Product Product and Solutions
2.8.4 Eli Lilly Biologic Medical Product Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Eli Lilly Recent Developments and Future Plans
2.9 Novartis
2.9.1 Novartis Details
2.9.2 Novartis Major Business
2.9.3 Novartis Biologic Medical Product Product and Solutions
2.9.4 Novartis Biologic Medical Product Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Novartis Recent Developments and Future Plans
2.10 Merck
2.10.1 Merck Details
2.10.2 Merck Major Business
2.10.3 Merck Biologic Medical Product Product and Solutions
2.10.4 Merck Biologic Medical Product Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 Merck Recent Developments and Future Plans
2.11 Sun
2.11.1 Sun Details
2.11.2 Sun Major Business
2.11.3 Sun Biologic Medical Product Product and Solutions
2.11.4 Sun Biologic Medical Product Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.11.5 Sun Recent Developments and Future Plans
2.12 3sbio
2.12.1 3sbio Details
2.12.2 3sbio Major Business
2.12.3 3sbio Biologic Medical Product Product and Solutions
2.12.4 3sbio Biologic Medical Product Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.12.5 3sbio Recent Developments and Future Plans
2.13 Changchun High Tech
2.13.1 Changchun High Tech Details
2.13.2 Changchun High Tech Major Business
2.13.3 Changchun High Tech Biologic Medical Product Product and Solutions
2.13.4 Changchun High Tech Biologic Medical Product Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.13.5 Changchun High Tech Recent Developments and Future Plans
2.14 CP Guojian
2.14.1 CP Guojian Details
2.14.2 CP Guojian Major Business
2.14.3 CP Guojian Biologic Medical Product Product and Solutions
2.14.4 CP Guojian Biologic Medical Product Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.14.5 CP Guojian Recent Developments and Future Plans
2.15 Biotech
2.15.1 Biotech Details
2.15.2 Biotech Major Business
2.15.3 Biotech Biologic Medical Product Product and Solutions
2.15.4 Biotech Biologic Medical Product Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.15.5 Biotech Recent Developments and Future Plans
2.16 Gelgen
2.16.1 Gelgen Details
2.16.2 Gelgen Major Business
2.16.3 Gelgen Biologic Medical Product Product and Solutions
2.16.4 Gelgen Biologic Medical Product Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.16.5 Gelgen Recent Developments and Future Plans
2.17 Innovent
2.17.1 Innovent Details
2.17.2 Innovent Major Business
2.17.3 Innovent Biologic Medical Product Product and Solutions
2.17.4 Innovent Biologic Medical Product Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.17.5 Innovent Recent Developments and Future Plans
2.18 Ganlee
2.18.1 Ganlee Details
2.18.2 Ganlee Major Business
2.18.3 Ganlee Biologic Medical Product Product and Solutions
2.18.4 Ganlee Biologic Medical Product Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.18.5 Ganlee Recent Developments and Future Plans
2.19 United Laboratories
2.19.1 United Laboratories Details
2.19.2 United Laboratories Major Business
2.19.3 United Laboratories Biologic Medical Product Product and Solutions
2.19.4 United Laboratories Biologic Medical Product Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.19.5 United Laboratories Recent Developments and Future Plans
2.20 Teva Pharmaceutical
2.20.1 Teva Pharmaceutical Details
2.20.2 Teva Pharmaceutical Major Business
2.20.3 Teva Pharmaceutical Biologic Medical Product Product and Solutions
2.20.4 Teva Pharmaceutical Biologic Medical Product Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.20.5 Teva Pharmaceutical Recent Developments and Future Plans
2.21 MYLAN
2.21.1 MYLAN Details
2.21.2 MYLAN Major Business
2.21.3 MYLAN Biologic Medical Product Product and Solutions
2.21.4 MYLAN Biologic Medical Product Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.21.5 MYLAN Recent Developments and Future Plans
2.22 Sun Pharma
2.22.1 Sun Pharma Details
2.22.2 Sun Pharma Major Business
2.22.3 Sun Pharma Biologic Medical Product Product and Solutions
2.22.4 Sun Pharma Biologic Medical Product Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.22.5 Sun Pharma Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Biologic Medical Product Revenue and Share by Players (2020-2025)
3.2 麻豆原创 Share Analysis (2024)
3.2.1 麻豆原创 Share of Biologic Medical Product by Company Revenue
3.2.2 Top 3 Biologic Medical Product Players 麻豆原创 Share in 2024
3.2.3 Top 6 Biologic Medical Product Players 麻豆原创 Share in 2024
3.3 Biologic Medical Product 麻豆原创: Overall Company Footprint Analysis
3.3.1 Biologic Medical Product 麻豆原创: Region Footprint
3.3.2 Biologic Medical Product 麻豆原创: Company Product Type Footprint
3.3.3 Biologic Medical Product 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Biologic Medical Product Consumption Value and 麻豆原创 Share by Type (2020-2025)
4.2 Global Biologic Medical Product 麻豆原创 Forecast by Type (2026-2031)
5 麻豆原创 Size Segment by Application
5.1 Global Biologic Medical Product Consumption Value 麻豆原创 Share by Application (2020-2025)
5.2 Global Biologic Medical Product 麻豆原创 Forecast by Application (2026-2031)
6 North America
6.1 North America Biologic Medical Product Consumption Value by Type (2020-2031)
6.2 North America Biologic Medical Product 麻豆原创 Size by Application (2020-2031)
6.3 North America Biologic Medical Product 麻豆原创 Size by Country
6.3.1 North America Biologic Medical Product Consumption Value by Country (2020-2031)
6.3.2 United States Biologic Medical Product 麻豆原创 Size and Forecast (2020-2031)
6.3.3 Canada Biologic Medical Product 麻豆原创 Size and Forecast (2020-2031)
6.3.4 Mexico Biologic Medical Product 麻豆原创 Size and Forecast (2020-2031)
7 Europe
7.1 Europe Biologic Medical Product Consumption Value by Type (2020-2031)
7.2 Europe Biologic Medical Product Consumption Value by Application (2020-2031)
7.3 Europe Biologic Medical Product 麻豆原创 Size by Country
7.3.1 Europe Biologic Medical Product Consumption Value by Country (2020-2031)
7.3.2 Germany Biologic Medical Product 麻豆原创 Size and Forecast (2020-2031)
7.3.3 France Biologic Medical Product 麻豆原创 Size and Forecast (2020-2031)
7.3.4 United Kingdom Biologic Medical Product 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Russia Biologic Medical Product 麻豆原创 Size and Forecast (2020-2031)
7.3.6 Italy Biologic Medical Product 麻豆原创 Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific Biologic Medical Product Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Biologic Medical Product Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Biologic Medical Product 麻豆原创 Size by Region
8.3.1 Asia-Pacific Biologic Medical Product Consumption Value by Region (2020-2031)
8.3.2 China Biologic Medical Product 麻豆原创 Size and Forecast (2020-2031)
8.3.3 Japan Biologic Medical Product 麻豆原创 Size and Forecast (2020-2031)
8.3.4 South Korea Biologic Medical Product 麻豆原创 Size and Forecast (2020-2031)
8.3.5 India Biologic Medical Product 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Southeast Asia Biologic Medical Product 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Australia Biologic Medical Product 麻豆原创 Size and Forecast (2020-2031)
9 South America
9.1 South America Biologic Medical Product Consumption Value by Type (2020-2031)
9.2 South America Biologic Medical Product Consumption Value by Application (2020-2031)
9.3 South America Biologic Medical Product 麻豆原创 Size by Country
9.3.1 South America Biologic Medical Product Consumption Value by Country (2020-2031)
9.3.2 Brazil Biologic Medical Product 麻豆原创 Size and Forecast (2020-2031)
9.3.3 Argentina Biologic Medical Product 麻豆原创 Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa Biologic Medical Product Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Biologic Medical Product Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Biologic Medical Product 麻豆原创 Size by Country
10.3.1 Middle East & Africa Biologic Medical Product Consumption Value by Country (2020-2031)
10.3.2 Turkey Biologic Medical Product 麻豆原创 Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Biologic Medical Product 麻豆原创 Size and Forecast (2020-2031)
10.3.4 UAE Biologic Medical Product 麻豆原创 Size and Forecast (2020-2031)
11 麻豆原创 Dynamics
11.1 Biologic Medical Product 麻豆原创 Drivers
11.2 Biologic Medical Product 麻豆原创 Restraints
11.3 Biologic Medical Product Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Biologic Medical Product Industry Chain
12.2 Biologic Medical Product Upstream Analysis
12.3 Biologic Medical Product Midstream Analysis
12.4 Biologic Medical Product Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Roche
Amgen
AbbVie
Pfizer
Sanofi-Aventis
Johnson & Johnson
Novo Nordisk
Eli Lilly
Novartis
Merck
Sun
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Ganlee
United Laboratories
Teva Pharmaceutical
MYLAN
Sun Pharma
听
听
*If Applicable.
